The safety committee of the European Medicines Agency is recommending that new restrictions be placed on the use of the multiple sclerosis drug Lemtrada (alemtuzumab) in light of reports of rare but serious side effects, including deaths. The latest recommendations replace temporary measures issued in April. They will be considered by the agency’s main scientific committee for a formal opinion.
